Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zygolide
- Development stage
- Unknown
- Lead developer
- Dechra Veterinary Products
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Zygolide is a veterinary dopamine receptor agonist developed by Dechra Veterinary Products for the control of clinical signs associated with Pituitary Pars Intermedia Dysfunction (PPID), also known as Equine Cushing's Disease, in horses. As a synthetic ergot derivative, it functions by stimulating dopamine receptors, which leads to a decrease in the plasma levels of adrenocorticotropic hormone (ACTH), melanocyte-stimulating hormone (MSH), and other pro-opiomelanocortin (POMC) peptides. Approved by the FDA in December 2025, Zygolide is the first generic bioequivalent option to the reference listed drug Prascend. It is formulated as 1 mg peppermint-flavored tablets with 360-degree scoring to facilitate precise dosing and ease of administration in equine patients.
- Brand names
- Zygolide
- Other names
- pergolide mesylate
02
Targets
DRD4 (Dopamine D4 Receptor)ADRA1D (α1D)ADRA2C (α2C)ADRA1A (α1A)HTR1B (5-Hydroxytryptamine Receptor 1B)HTR1D (5-hydroxytryptamine receptor 1D)HTR2A (Serotonin receptor 5-HT2A)ADRA2A (α2A)ADRA2B (α2B)DRD1 (Dopamine D1 Receptor)HTR2C (5-hydroxytryptamine 2C receptor)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)ADRA1B (α1B)DRD5 (Dopamine D5 Receptor)HTR2B (5-Hydroxytryptamine Receptor 2B)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))
Beyond the preview
Go deeper on Zygolide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zygolide.